PaxMedica, Inc. (PXMD)

NASDAQ: PXMD · IEX Real-Time Price · USD
0.752
-0.009 (-1.13%)
At close: Apr 22, 2024, 4:00 PM
0.719
-0.033 (-4.44%)
After-hours: Apr 22, 2024, 7:57 PM EDT
-1.13%
Market Cap 5.62M
Revenue (ttm) n/a
Net Income (ttm) -18.29M
Shares Out 7.47M
EPS (ttm) -11.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 573,063
Open 0.770
Previous Close 0.761
Day's Range 0.752 - 0.850
52-Week Range 0.372 - 29.750
Beta n/a
Analysts Strong Buy
Price Target 3.00 (+298.78%)
Earnings Date May 13, 2024

About PXMD

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is dev... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2022
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PXMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PXMD stock is "Strong Buy" and the 12-month stock price forecast is $3.0.

Price Target
$3.0
(298.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN --  PaxMedica , Inc. (NASDAQ:  PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today ann...

6 days ago - GlobeNewsWire

Why is PaxMedica (PXMD) stock surging today?

PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts.

10 days ago - Invezz

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announ...

11 days ago - GlobeNewsWire

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced...

5 weeks ago - GlobeNewsWire

PaxMedica Releases Fireside Chat Video with CEO Howard Weisman

TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Firesi...

4 months ago - Accesswire

PaxMedica Announces Closing of $7.0 Million Public Offering

TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, t...

5 months ago - Accesswire

PaxMedica Announces Pricing of $7.0 Million Public Offering

TARRYTOWN, NY / ACCESSWIRE / November 20, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, t...

5 months ago - Accesswire

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that it ...

5 months ago - GlobeNewsWire

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive ...

5 months ago - Accesswire

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of rese...

5 months ago - Accesswire

PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)

TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- via IBN --  PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has eng...

6 months ago - GlobeNewsWire

PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological diso...

6 months ago - GlobeNewsWire

PaxMedica Announces 1-for-17 Reverse Stock Split

TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug thera...

6 months ago - GlobeNewsWire

PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN --  PaxMedica , Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatr...

6 months ago - GlobeNewsWire

PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

Key Guidance Regarding NDA Filing Obtained TARRYTOWN, NY / ACCESSWIRE / October 26, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company, announced the completion of a type...

6 months ago - Accesswire

PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical compan...

8 months ago - GlobeNewsWire

PaxMedica Appoints David Hough M.D. as Chief Medical Officer

Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stag...

8 months ago - GlobeNewsWire

PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update

TARRYTOWN, NY, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug...

9 months ago - GlobeNewsWire

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

TARRYTOWN, NY, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic dru...

9 months ago - GlobeNewsWire

PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as well as additional offerings for People diagnosed with Autism and their Families.

10 months ago - GlobeNewsWire

PaxMedia hires ShareIntel to look into recent stock weakness, after a 45% plunge amid an 8-day losing streak

Shares of PaxMedia Inc. PXMD, -11.91% bounced 2.0% in premarket trading Thursday, after the biopharmaceutical company, which focuses on treatments of Autism Spectrum Disorder (ASD) said it was not awa...

10 months ago - Market Watch

PaxMedica Comments on Common Stock Volatility

Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on ...

10 months ago - GlobeNewsWire

PaxMedica CEO Interviewed by The BRAIN Foundation

Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the d...

10 months ago - GlobeNewsWire

PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder

TARRYTOWN, NY, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug...

11 months ago - GlobeNewsWire

PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder

Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Concept Study Based on one of PaxMedica's Proprietary Pipeline Candidates TARRYTOWN, NY, June 08, 20...

11 months ago - GlobeNewsWire